The U.S. Food & Drug Administration (FDA) has given W. L. Gore & Associates, Inc. (GORE) clearance to market its GORE PROPATEN Vascular Graft for peripheral use, including lower-limb bypass and dialysis access surgery.
The GORE PROPATEN Vascular Graft is coated with the Carmeda® bioactive surface (CBAS®) and is the first ePTFE vascular graft that reduces thrombosis —or clotting. It is designed to address the clinical problem of thrombotic vascular graft failure.
sitemap
home
contact
